This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Autoimmune disease

Autoimmune disease

IL-7; IL-7 receptor (IL-7R; CD127)

In vitro and mouse studies suggest soluble IL-7R can enhance the activity of IL-7, a cytokine that plays roles in autoimmune disease and antiviral immunity. In cultured T cells, soluble IL-7R plus IL-7 increased the duration of IL-7 activity compared with IL-7 alone. In a mouse model for experimental autoimmune encephalitis (EAE), IL-7 plus soluble IL-7R exacerbated disease pathology. Next steps include evaluating soluble IL-7R as a biomarker for multiple sclerosis (MS) and using soluble IL-7R to enhance the antiviral effect of IL-7 in models for infection.
Cytheris S.A.'s CYT107 recombinant IL-7 is in Phase II trials to treat progressive multifocal leukoencephalopathy (PML).

SciBX 6(19); doi:10.1038/scibx.2013.457
Published online May 16, 2013

Unpatented; licensing status not applicable

Lundström, W. et al. Proc. Natl. Acad. Sci. USA; published online April 22, 2013;
doi:10.1073/pnas.1222303110
Contact: Crystal L. Mackall, National Cancer Institute, Bethesda, Md.
e-mail:
mackallc@mail.nih.gov